Related Experiment Videos
A clinical study of nafazatrom in advanced human breast cancer
A L Jones1, T J Powles, G V Forgeson
1Royal Marsden Hospital, Institute of Cancer Research, Sutton, Surrey, UK.
Abstract:
Prostaglandins (PGs) have been shown to inhibit tumour metastases in experimental animal systems. Nafazatrom is a pyrazolinone derivative that increases endogenous prostacyclin (PGI2) and has experimental anti-cancer activity. In the present study, nafazatrom was given to 47 women with advanced breast cancer; objective remission of metastases was seen in 2 patients and stabilisation of disease in 1 case. Nafazatrom was safe and well tolerated.
Insights
Nafazatrom, a drug increasing prostacyclin (PGI2), showed potential in treating advanced breast cancer by inducing remission in some patients. The drug was found to be safe and well-tolerated in the study group.
Area of Science:
- Oncology
- Pharmacology
Background:
- Prostaglandins (PGs) demonstrate anti-metastatic properties in preclinical models.
- Nafazatrom, a pyrazolinone derivative, enhances endogenous prostacyclin (PGI2) production.
- Nafazatrom exhibits experimental anti-cancer effects.
Purpose of the Study:
- To evaluate the efficacy and safety of nafazatrom in women with advanced breast cancer.
- To assess the impact of nafazatrom on tumor metastasis and disease stabilization.
Main Methods:
- A clinical study involving 47 women diagnosed with advanced breast cancer.
- Administration of nafazatrom to the patient cohort.
- Monitoring for objective tumor remission and disease stabilization.
Main Results:
- Objective remission of metastases was observed in 2 out of 47 patients.
- Disease stabilization was noted in 1 patient.
- Nafazatrom was determined to be safe and well-tolerated by all participants.
Conclusions:
- Nafazatrom demonstrates preliminary efficacy in a subset of patients with advanced breast cancer.
- The drug's safety profile suggests it is a viable option for further investigation in breast cancer treatment.
- Further research is warranted to explore the therapeutic potential of nafazatrom and prostacyclin modulation in oncology.